Abstract
Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.
Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.
Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.
Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 90-91 |
| Number of pages | 2 |
| Journal | Cornea |
| Volume | 31 |
| Issue number | 1 |
| State | Published - Jan 1 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Certolizumab
- Scleritis
- Tumor necrosis factor alpha inhibitor
ASJC Scopus subject areas
- Ophthalmology
Cite this
Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. / Tlucek, Paul S.; Stone, Donald U.
In: Cornea, Vol. 31, No. 1, 01.01.2012, p. 90-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis
AU - Tlucek, Paul S.
AU - Stone, Donald U.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.
AB - Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.
KW - Certolizumab
KW - Scleritis
KW - Tumor necrosis factor alpha inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84856505045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856505045&partnerID=8YFLogxK
M3 - Article
C2 - 21941174
AN - SCOPUS:84856505045
VL - 31
SP - 90
EP - 91
JO - Cornea
JF - Cornea
SN - 0277-3740
IS - 1
ER -